about
REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.Are there specific translational challenges in regenerative medicine? Lessons from other fields.Communication of results and disclosure of incidental findings in longitudinal paediatric research.The impact of European embryonic stem cell patent decisions on research strategies.The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom.The European Medicines Agency: a public health European agency?Access to advanced therapy medicinal products in the EU: where do we stand?[Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]Chapitre 6. Cells? safety in Europe: Towards an ethical safetyThe emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics[Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation]
P50
Q30355329-E422E5C1-0E54-431E-9F84-A1DCB5CE9393Q38626131-4F54319C-6454-411D-B816-62A51772C691Q44041326-AEB8B2A7-A50C-4C14-A265-2B7FC1A62CCDQ48236946-2410CA7C-AFEA-44DD-93EA-73BEB6B28CC1Q48451307-FCEC7A21-62D8-45A1-AD2B-B152C12CD5F8Q84833864-C3711E43-1360-41F2-9654-6DFB927A2E0BQ84835699-07A44BAF-F802-4366-B8D9-38DC16E4570BQ88100270-DD03A9CD-B85E-4BCE-ACD1-E03C8DE4D18FQ88117472-36C8F0FA-82B5-4A72-AC17-84CE4E954080Q89131306-FB281200-5C4F-4806-9699-D3DD89F21D54Q91609402-D8753540-8301-42C1-BE58-5F51725DCF5D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-4365-2143
@en
name
Aurélie Mahalatchimy
@ast
Aurélie Mahalatchimy
@en
Aurélie Mahalatchimy
@es
Aurélie Mahalatchimy
@nl
type
label
Aurélie Mahalatchimy
@ast
Aurélie Mahalatchimy
@en
Aurélie Mahalatchimy
@es
Aurélie Mahalatchimy
@nl
prefLabel
Aurélie Mahalatchimy
@ast
Aurélie Mahalatchimy
@en
Aurélie Mahalatchimy
@es
Aurélie Mahalatchimy
@nl
P106
P1153
52364442200
P21
P31
P496
0000-0002-4365-2143